Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Oct
17
UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis
Oct
12
Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa
Oct
04
UCB presents late-breaking posters at Child Neurology Society Meeting
Jul
21
UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive
Jun
27
UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis
Apr
20
UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting
Apr
17
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance
Jan
18
Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis
Jan
06
UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review